Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
14
09
2020
revised:
06
01
2021
accepted:
15
01
2021
pubmed:
8
8
2021
medline:
1
1
2022
entrez:
7
8
2021
Statut:
ppublish
Résumé
Latent tuberculosis infection (LTBI) is one of the most prevalent infections globally and can lead to the development of active tuberculosis disease. In many low-burden countries, LTBI is concentrated within migrant populations often because of a higher disease burden in the migrant's country of origin. National programmes consequently focus on screening and treating LTBI in migrants to prevent future tuberculosis cases; however, how effective these programmes are is unclear. We aimed to assess LTBI treatment initiation and outcomes among migrants, and the factors that influence both. For this systematic review and meta-analysis, we searched Embase, MEDLINE, and Global Health, and manually searched grey literature from Jan 1, 2000, to April 21, 2020. We included primary research articles reporting on LTBI treatment initiation or completion, or both, in migrants and excluded articles in which data were not stratified by migrant status, or in which the data were related to outcomes before 2000. There were no geographical or language restrictions. All included studies were quality appraised using recognised tools depending on their design, and we assessed the heterogeneity of analyses using I 2199 publications were retrieved screened, after which 39 publications from 13 mostly high-income, low-burden countries were included in our analyses, with treatment initiation and completion data reported for 31 598 migrants positive for LTBI, with not all articles reporting the full pathway from initiation to completion. The pooled estimate for the true proportion of migrants testing positive who initiated treatment was 69% (95% CI 51-84; I Although our analysis highlights that LTBI treatment initiation and completion in migrants has improved considerably from 2010-20, there is still room for improvement, with drop out reported along the entire treatment pathway. The delivery of these screening and treatment programmes will require further strengthening if the targets to eradicate tuberculosis in low-incidence countries are to be met, with greater focus needed on engaging migrants more effectively in the clinic and understanding the diverse and unique barriers and facilitators to migrants initiating and completing treatment. European Society of Clinical Microbiology and Infectious Diseases, the Rosetrees Trust, the National Institute for Health Research, and the Academy of Medical Sciences.
Sections du résumé
BACKGROUND
Latent tuberculosis infection (LTBI) is one of the most prevalent infections globally and can lead to the development of active tuberculosis disease. In many low-burden countries, LTBI is concentrated within migrant populations often because of a higher disease burden in the migrant's country of origin. National programmes consequently focus on screening and treating LTBI in migrants to prevent future tuberculosis cases; however, how effective these programmes are is unclear. We aimed to assess LTBI treatment initiation and outcomes among migrants, and the factors that influence both.
METHODS
For this systematic review and meta-analysis, we searched Embase, MEDLINE, and Global Health, and manually searched grey literature from Jan 1, 2000, to April 21, 2020. We included primary research articles reporting on LTBI treatment initiation or completion, or both, in migrants and excluded articles in which data were not stratified by migrant status, or in which the data were related to outcomes before 2000. There were no geographical or language restrictions. All included studies were quality appraised using recognised tools depending on their design, and we assessed the heterogeneity of analyses using I
FINDINGS
2199 publications were retrieved screened, after which 39 publications from 13 mostly high-income, low-burden countries were included in our analyses, with treatment initiation and completion data reported for 31 598 migrants positive for LTBI, with not all articles reporting the full pathway from initiation to completion. The pooled estimate for the true proportion of migrants testing positive who initiated treatment was 69% (95% CI 51-84; I
INTERPRETATION
Although our analysis highlights that LTBI treatment initiation and completion in migrants has improved considerably from 2010-20, there is still room for improvement, with drop out reported along the entire treatment pathway. The delivery of these screening and treatment programmes will require further strengthening if the targets to eradicate tuberculosis in low-incidence countries are to be met, with greater focus needed on engaging migrants more effectively in the clinic and understanding the diverse and unique barriers and facilitators to migrants initiating and completing treatment.
FUNDING
European Society of Clinical Microbiology and Infectious Diseases, the Rosetrees Trust, the National Institute for Health Research, and the Academy of Medical Sciences.
Identifiants
pubmed: 34363771
pii: S1473-3099(21)00052-9
doi: 10.1016/S1473-3099(21)00052-9
pmc: PMC8612939
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1701-1712Subventions
Organisme : Medical Research Council
ID : MR/V027549/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N013638/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests SH is a freelance Senior Editor for The Lancet Infectious Diseases and other Lancet journals. All other authors declare no competing interests.
Références
Epidemiol Infect. 1997 Oct;119(2):183-201
pubmed: 9363017
BMC Public Health. 2013 Sep 28;13:894
pubmed: 24073620
Eur Respir J. 2019 Nov 28;54(5):
pubmed: 31537698
PLoS One. 2019 May 21;14(5):e0216234
pubmed: 31112542
Int J Tuberc Lung Dis. 2015 May;19(5):565-9
pubmed: 25868025
ERJ Open Res. 2018 Mar 23;4(1):
pubmed: 29577042
Int J Infect Dis. 2010 Apr;14(4):e292-7
pubmed: 19656705
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1044-52
pubmed: 25265362
J Immigr Minor Health. 2016 Apr;18(2):292-300
pubmed: 25784140
Eur Respir J. 2018 Jul 11;52(1):
pubmed: 29794133
BMJ Paediatr Open. 2019 Sep 11;3(1):e000516
pubmed: 31646192
Lancet Infect Dis. 2016 Nov;16(11):1269-1278
pubmed: 27522233
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Int J Tuberc Lung Dis. 2019 May 1;23(5):579-586
pubmed: 31097066
Front Public Health. 2019 Mar 21;7:57
pubmed: 30949466
Conn Med. 2017 May;81(5):291-298
pubmed: 29738131
Int J Tuberc Lung Dis. 2015 Jul;19(7):799-804
pubmed: 26056104
Int J Tuberc Lung Dis. 2008 May;12(5):480-92
pubmed: 18419882
Am J Epidemiol. 1974 Feb;99(2):131-8
pubmed: 4810628
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Emerg Microbes Infect. 2016 Feb 03;5:e10
pubmed: 26839146
Conn Med. 2013 Jun-Jul;77(6):325-30
pubmed: 23923248
Lancet. 2016 Nov 19;388(10059):2510-2518
pubmed: 27742165
Int J Tuberc Lung Dis. 2017 Feb 1;21(2):175-180
pubmed: 28234081
Chest. 2006 Dec;130(6):1712-7
pubmed: 17166986
J Paediatr Child Health. 2018 Aug;54(8):834-839
pubmed: 29442397
Eur Respir J. 2019 Oct 31;54(4):
pubmed: 31413161
Int J Tuberc Lung Dis. 2017 Apr 1;21(4):432-437
pubmed: 28284259
J Community Health Nurs. 2007 Fall;24(3):191-8
pubmed: 17650988
BMC Public Health. 2012 Jun 21;12:468
pubmed: 22720842
Tuberc Respir Dis (Seoul). 2019 Oct;82(4):306-310
pubmed: 31172709
Int J Tuberc Lung Dis. 2013 Mar;17(3):326-32
pubmed: 23407221
Can Respir J. 2016;2016:8249843
pubmed: 28127230
Science. 2014 Mar 28;343(6178):1520-2
pubmed: 24675962
Scand J Public Health. 2010 May;38(3):275-82
pubmed: 19914972
J Immigr Minor Health. 2015 Feb;17(1):56-65
pubmed: 23907316
PLoS One. 2019 Jul 1;14(7):e0219252
pubmed: 31260502
PLoS One. 2012;7(11):e48900
pubmed: 23139824
BMC Infect Dis. 2016 May 17;16:204
pubmed: 27184748
Infect Dis (Lond). 2018 Sep;50(9):678-686
pubmed: 29620426
BMC Infect Dis. 2018 Nov 19;18(1):587
pubmed: 30453946
Int J Tuberc Lung Dis. 2019 May 1;23(5):563-570
pubmed: 31097064
BMC Infect Dis. 2009 Mar 24;9:34
pubmed: 19317899
PLoS One. 2014 May 09;9(5):e97366
pubmed: 24816576
N Engl J Med. 2019 Mar 14;380(11):1001-1011
pubmed: 30865794
Int J Tuberc Lung Dis. 2010 Sep;14(9):1104-11
pubmed: 20819254
Int J Tuberc Lung Dis. 2008 Feb;12(2):160-7
pubmed: 18230248
Med J Aust. 2011 Jun 6;194(11):579-82
pubmed: 21644870
Public Health Action. 2018 Sep 21;8(3):135-140
pubmed: 30271730
Lancet Infect Dis. 2018 Sep;18(9):e259-e271
pubmed: 29778396
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Int J Family Med. 2015;2015:546042
pubmed: 26690263
Euro Surveill. 2019 Oct;24(44):
pubmed: 31690363
Thorax. 2017 Feb;72(2):180-182
pubmed: 27742873
Pediatrics. 2006 Feb;117(2):e148-56
pubmed: 16452324
Am J Respir Crit Care Med. 2006 Sep 15;174(6):717-21
pubmed: 16809632
PLoS One. 2017 Nov 1;12(11):e0186588
pubmed: 29091917
Am J Public Health. 2014 Apr;104(4):e95-e102
pubmed: 24524534
MMWR Recomm Rep. 2020 Feb 14;69(1):1-11
pubmed: 32053584
BMC Med. 2016 Mar 23;14:48
pubmed: 27004556
Eur Respir J. 2018 Jan 11;51(1):
pubmed: 29326327
Euro Surveill. 2018 Apr;23(14):
pubmed: 29637889
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810
BMC Infect Dis. 2014 Dec 03;14:657
pubmed: 25466442